B3Trade
US announces 100% tariff on branded drug imports, with a plant-building exemption
The White House said branded and patented medicines made abroad would face a 100% tariff from October 1, unless the maker is building a plant in the United States.
Dateline
Washington, DC
Container cranes, Bremerhaven Photo: H. Zell, CC BY-SA 3.0, via Wikimedia Commons (cropped)
In one lineA factory under construction became a way to avoid a tariff.
What was announced
On September 25, 2025, the US president said that from October 1 any branded or patented pharmaceutical product imported into the United States would face a 100% tariff, unless the company is "building" a manufacturing plant in the US. Generic medicines were not included.
The exemption
The key line was the exemption. Companies that had broken ground or were under construction would not pay. Most large drug companies had already announced US plants in 2025.
Deals on top
Separate trade agreements changed the picture for some countries. The EU and Japan had agreed caps of about 15% on many goods including medicines. Several companies also struck pricing deals with the government that included tariff relief.
For peptide medicines
GLP-1 drugs are among the biggest branded imports by value. Ingredient made in Denmark or Switzerland and pens filled in Europe would, in theory, fall under the rule.
The caveat
Implementation details came later and changed. Check current guidance before relying on any rate.
What it changes for supply
The rule rewards moving production to the US. It explains part of the rush of US plant announcements in 2025.
Still open
How "building a plant" is defined, how trade deals with the EU and Japan apply, and whether the tariff is enforced as announced.
SourceWhite House announcement, September 25, 2025, and later trade guidance
Peptide Global covers how medicines are made and traded. Nothing here is medical advice.
